Author:
,Brady Michael T.,Byington Carrie L.,Davies H. Dele,Edwards Kathryn M.,Jackson Mary Anne,Maldonado Yvonne A.,Murray Dennis L.,Orenstein Walter A.,Rathore Mobeen H.,Sawyer Mark H.,Schutze Gordon E.,Willoughby Rodney E.,Zaoutis Theoklis E.,Ralston Shawn L.,Lieberthal Allan S.,Meissner H. Cody,Alverson Brian K.,Baley Jill E.,Gadomski Anne M.,Johnson David W.,Light Michael J.,Maraqa Nizar F.,Mendonca Eneida A.,Phelan Kieran J.,Zorc Joseph J.,Stanko-Lopp Danette,Hernández-Cancio Sinsi
Abstract
Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology and Child Health
Reference11 articles.
1. Choosing wisely: helping physicians and patients make smart decisions about their care.;Cassel;JAMA,2012
2. Medical professionalism in the new millennium: a physician charter.;ABIM Foundation. American Board of Internal Medicine;Ann Intern Med,2002
3. Promoting population health through financial stewardship.;Ubel;N Engl J Med,2014
4. Technical report: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.;American Academy of Pediatrics, Committee on Infectious Diseases and Bronchiolitis Guidelines Committee;Pediatrics,2014
5. Respiratory syncytial virus.;American Academy of Pediatrics,2012